Monthly Archives: February 2019

Biomarker-based management improves outcomes in Crohn’s disease (CD) compared to symptoms alone, but existing biomarkers have limitations. We assessed the diagnostic performance of the Mucosal Healing Index (MHI; PROMETHEUS MonitrTM) for detecting mu… Continue reading →

The course of Inflammatory Bowel Disease (IBD incorporating both Crohn’s Disease and ulcerative colitis) varies substantially between affected individuals, but reliable prognostic markers are not available in clinical practice. This hinders disease m… Continue reading →

Identifying active small bowel Crohn’s Disease (CD) is often challenging due various reasons. The location of Crohn’s disease and often the disease process itself make direct visualization difficult. Fecal calprotectin (FCP) is a well-established m… Continue reading →

There is increasing emphasis on early diagnosis and intervention in inflammatory bowel disease (IBD), in particular Crohn’s disease (CD). Early treatment with effective medications can prevent IBD progression towards complications, surgery and disabi… Continue reading →

Multiplex polymerase chain reaction based stool assays for gastrointestinal pathogens (GI PCR) allow for the timely and accurate detection of enteric infections that were poorly characterized by conventional means such as stool culture. Despite the in… Continue reading →

Approximately 1.6 million Americans suffer from inflammatory bowel diseases (IBD); Ulcerative colitis (UC) and Crohn’s disease (CD). The goal of IBD therapy is to induce deep remission characterized by resolution of both endoscopic and histologic abn… Continue reading →

The efficacy and safety of mirikizumab (miri), an IL-23p19 antibody, has been evaluated in moderate-to-severe ulcerative colitis (UC) in a phase 2, randomized, double-blind, placebo (pbo)-controlled trial (AMAC, NCT02589665; presented at DDW 2018). Mir… Continue reading →

Ustekinumab (UST) is a human IgG1κ monoclonal antibody that binds to the p40 protein subunit, which is common to both IL-12 & IL-23 cytokines. It is approved for use in treatment of moderately to severely active Crohn’s disease (CD). The primary endpoint data (Wk 44) from the pivotal Phase 3 study, IM-UNITI, has been previously reported. We examined efficacy of UST after 1 year of maintenance therapy (Wk 56). Continue reading →

Etrolizumab, a monoclonal antibody to the β7 integrin, inhibits both α4β7:mucosal addressin cell adhesion molecule 1 (MAdCAM-1)–mediated lymphocyte trafficking to the gut mucosa and αEβ7:E-cadherin–mediated lymphocyte retention. In patients wi… Continue reading →

SHP647, a fully human IgG2 monoclonal antibody, binds to human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to reduce lymphocyte homing to the gastrointestinal tract. SHP647 was well tolerated in a randomized, double-blind phase 2 trial (TURAN… Continue reading →